Cardiac Function in LCFAOD Improves with Triheptanoin

Referencing a study by Jerry Vockley, MD, PhD, at the International Network for Fatty Acid Oxidation Research and Management (INFORM), data appears to show that treatment in critically ill patients with LCFAODs could improve with triheptanoin.

Triheptanoin, a synthetic triglyceride, has shown its digestion produces no symptoms in patients with LCFAOD. Most users tolerated the drug without experiencing any important adverse effects.

The full article can be found here.